Biotech Acquisition Company (BIOT)

NASDAQ: BIOT · IEX Real-Time Price · USD
9.96
0.01 (0.05%)
May 18, 2022 9:57 AM EDT - Market open
Market Cap286.21M
Revenue (ttm)n/a
Net Income (ttm)-6.86M
Shares Out28.75M
EPS (ttm)-0.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,471
Open9.96
Previous Close9.95
Day's Range9.96 - 9.96
52-Week Range9.61 - 9.96
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About BIOT

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

IndustryBlank Check / SPAC
IPO DateJan 26, 2021
Employees4
Stock ExchangeNASDAQ
Ticker SymbolBIOT
Full Company Profile

Financial Performance

Financial Statements

News

Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the Amer...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ATS2022--Blade Therapeutics announces new data from preclinical studies that highlight differentiating characteristics of cudetaxestat in poster at ATS 2022.

2 hours ago - Business Wire

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Societ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ATS2022--Blade Therapeutics presented data from phase 1 & preclinical DDI studies of cudetaxestat at American Thoracic Society 2022 International Conference

2 days ago - Business Wire

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4...

Extraordinary General Meeting of BAC's shareholders is scheduled for June 1, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed "Blade Biotherapeutics, Inc." upon Business Combinatio...

1 week ago - PRNewsWire

Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Prop...

NEW YORK , April 4, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today annou...

1 month ago - PRNewsWire

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade Therapeutics, Inc. (“Blade” or “Company”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating...

1 month ago - Business Wire

Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Soci...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ATS2022--Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerati...

1 month ago - Business Wire

Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger ...

NEW YORK , March 16, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today anno...

2 months ago - PRNewsWire

Blade Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #OPCOHC2022--Blade to present at Oppenheimer's 32nd Annual Healthcare Conference on March 15 and at Barclays Global Healthcare Conference on March 16, 2022.

2 months ago - Business Wire

Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cude...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade Therapeutics, Inc. today announced the successful completion of a phase 1 drug-drug interaction clinical study of cudetaxestat.

4 months ago - Business Wire

Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Propos...

NEW YORK, Jan. 3, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announc...

4 months ago - PRNewsWire

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Aut...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade announces positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat.

5 months ago - Business Wire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Bi...

New York, New York--(Newsfile Corp. - November 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Biotech Acquisition Company (NASDAQ: ...

6 months ago - Newsfile Corp

Biotech Acquisition Company Announces Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 1...

NEW YORK, March 15, 2021 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOTU) (the "Company") announced that, commencing March 18, 2021, holders of the units sold in the Company's initial public ...

1 year ago - PRNewsWire

Biotech Acquisition Company Announces Closing of $230,000,000 Initial Public Offering

New York, NY, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Biotech Acquisition Company (the “Company”) announced today that it has closed its initial public offering of 23,000,000 units, including 3,000,000 units ...

1 year ago - GlobeNewsWire

Biotech Acquisition Company Announces Pricing of $200 Million Initial Public Offering

New York, NY, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Biotech Acquisition Company (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acqui...

1 year ago - GlobeNewsWire